SAB Biotherapeutics enters sales agreement with UBS Securities.

SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has entered a sales agreement with UBS Securities. The company focuses on developing fully human immunoglobulins to treat and prevent immune and autoimmune disorders. Its lead asset, SAB-142, targets type 1 diabetes with a disease-modifying therapeutic approach. The company's pipeline also includes SAB-176, a multivalent, broadly neutralizing human polyclonal IgG therapeutic candidate for severe influenza treatment or prevention.